Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of NPM1-mutated acute myeloid leukemia
News
Kronos Bio Appoints Pasit Phiasivongsa, Ph.D., as Senior Vice President, Pharmaceutical Development
SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Pasit Phiasivongsa, Ph.D., as sen… […]
News
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors
SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of veteran biopharmaceutical executi… […]
